Literature DB >> 1893350

Adjuvant whole-abdominal radiation therapy in uterine papillary serous carcinoma.

A H Frank1, P C Tseng, B G Haffty, D P Papadopoulos, B M Kacinski, S W Dowling, M L Carcangiu, E I Kohorn, J T Chambers, S K Chambers.   

Abstract

Nine patients from 34 to 74 years of age (median, 67 years of age) with uterine papillary serous carcinoma (UPSC) were treated with whole-abdominal radiation therapy (WART) on an adjuvant basis after cytoreductive surgery. All patients were treated with megavoltage photons to an abdominopelvic field to a median dose of 2500 cGy, with continued treatment to a whole pelvic field to a median dose of 4500 cGy. Three patients received additional boost to the vaginal apex. Follow-up time ranged from 6 to 31 months (median, 25 months) after completion of WART. Six patients had recurrent disease at 5 to 20 months (median, 7.5 months). Four of these patients died of their disease during the follow-up period. Three of six patients in whom treatment failed had disease at the vaginal apex. None of these patients received boost radiation therapy to that site. In contrast, two of three patients remaining disease free were treated with additional vaginal apex irradiation. Based on these results, the authors do not routinely recommend WART for adjuvant treatment of UPSC. They do, however, recommend vaginal apex irradiation for these patients.

Entities:  

Mesh:

Year:  1991        PMID: 1893350     DOI: 10.1002/1097-0142(19911001)68:7<1516::aid-cncr2820680709>3.0.co;2-x

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

Review 1.  Therapeutic dilemmas in the management of uterine papillary serous carcinoma.

Authors:  Felice D Lackman; Peter S Craighead
Journal:  Curr Treat Options Oncol       Date:  2003-04

2.  Management of women with surgically staged 1 uterine papillary serous cancer.

Authors:  Laurie Elit; Andre Laroche; Lauren Smith; John Mazurka; Francois Moens; Jan Hauspy; Waldo Jimenez
Journal:  ISRN Obstet Gynecol       Date:  2011-09-11

3.  Evaluation of adjuvant therapy in women with uterine papillary serous cancer.

Authors:  Hamed Al Husaini; Hussein Soudy; Alaa Darwish; Mohamed Ahmed; Amin Eltigani; Wael Edesa; Mahmoud Abdelsalam
Journal:  Ann Saudi Med       Date:  2012 Jan-Feb       Impact factor: 1.526

4.  Stage III uterine serous carcinoma: modern trends in multimodality treatment.

Authors:  Jessie Y Li; Melissa R Young; Gloria Huang; Babak Litkouhi; Alessandro Santin; Peter E Schwartz; Shari Damast
Journal:  J Gynecol Oncol       Date:  2020-02-17       Impact factor: 4.401

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.